Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 NEXXfFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDTT21GVC13IH3lcIFvd22jIHPlcIwhdGmwZYOsJGVFPTB;Mz6wNGUuODhizszN NUHlT2g3OTh5NUO1NC=>
A-549 MkDjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGPQO2dEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= MkS2NVg4PTN3MB?=
MCF-7 Mk\JS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTWR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= M{K4fFE5PzV|NUC=
HT-29 NVvPb41oT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3j2V2N6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJGhVNTJ7IHPvcI9vKGGmZX7vZ4Fz[2mwb33hJINmdGxibHnu[ZMtKEWGNUC9NU4zOEVvME[g{txO NFu5TG0yQDd3M{Ww
MLM melanoma cell MlHtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkjYR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWxOKG2nbHHuc41iKGOnbHygcIlv\XNuIFXEOVA:OS52MFWtNFYh|ryP NYjwXGpzOTh5NUO1NC=>
M14 NUTLUVMzS3m2b4TvfIlkcXS7IHHzd4F6 NHrMUZpKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhf2G|IITld5Rm\CCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINidmOncjCoUVE1MSClZXzsJIxqdmVuIFfJOVA:OC5yMECxJO69VQ>? NHHBRnkyOjd{OU[0NC=>
SK-OV3 NUH3fFBUS3m2b4TvfIlkcXS7IHHzd4F6 MYTJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImgeIV{fGWmIHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgLHNMNU:YMzmgZ4VtdCCuaX7lMEBIUTVyPUCuNFAxOSEQvF2= NV;CenhDOTJ5Mkm2OFA>
HL60 cells NV\ablFuS3m2b4TvfIlkcXS7IHHzd4F6 MUW3NkBp MoTMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= NFLtVnYzODd|MUO1OS=>
SK-OV-3 M3PiWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn7uOFghcA>? M2\TRWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNFE{KM7:TR?= NFzRT48yQDd{MkGyOy=>
HepG2 cells M364b2N6fG:2b4jpZ4l1gSCjc4PhfS=> NY\TSnhjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVA:OC5yMECxOEDPxE1? NVvhPJk4OTdzMkewOlE>
ZR-75-1 NUDoemloS3m2b4TvfIlkcXS7IHHzd4F6 NV25XoZLS3m2b4TvfIlkcXS7IHHnZYlve3RiWmKtO|UuOSClZXzsJIxqdmVuIFnDOVA:OC5yMECyOEDPxE1? MnG3NVczPDl4NEm=
HeLa cell MmDHR5l1d3SxeHnjbZR6KGG|c3H5 NWnJUY9rS3m2b4TvfIlkcXS7IHHnZYlve3RiSHXMZUBk\WyuIHzpcoUtKEmFNUC9NE4xODB|IN88US=> MUGxO|I1QTZ2OR?=
HCT116 cell M1Xob2N6fG:2b4jpZ4l1gSCjc4PhfS=> NFzVW4VEgXSxdH;4bYNqfHliYXfhbY5{fCCKQ2SxNVYh[2WubDDsbY5mNCCLQ{WwQVAvODByM{Wg{txO NWDQXHRlOTd{NEm2OFk>
KBV1 cells NYPhepFXS3m2b4TvfIlkcXS7IHHzd4F6 MXq3NkBp MkLiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geolv[myjc4TpcoUuemW|aYP0ZY51KEuEVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMESg{txO MUWyNFc{OTN3NR?=
SKOV3 MYjDfZRwfG:6aXPpeJkh[XO|YYm= MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? MV6yOFAyPjByMh?=
SKOV3 cells MmfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN MnzxNlM4PzJ|MEm=
HeLa cells MYPDfZRwfG:6aXPpeJkh[XO|YYm= MmXnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC1NUDPxE1? NETLRo8yQTh5OUe1PC=>
DU145 cells MoPFR5l1d3SxeHnjbZR6KGG|c3H5 MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC1OEDPxE1? MYCyOFAyPjByMh?=
DU145 cells M3jsXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV3S[lRUT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMEW0JO69VQ>? MX:yN|c4OjNyOR?=
SK-N-BE NEG2dnhRem:uaX\ldoF1cW:wIHHzd4F6 NHTxZ2Q4OiCq NX7IRXFkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP M4D6clIzOzJ7NU[x
NCIH460 cells MofsR5l1d3SxeHnjbZR6KGG|c3H5 NV7VXnQxPDhiaB?= MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2lJPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB4IN88US=> MV2xPFMxOzh2OR?=
KB-VIN10 cells NGHJUGdRem:uaX\ldoF1cW:wIHHzd4F6 NELN[4o4OiCq NIXJeJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP NYPNW3BvOjF4NEG3NFA>
HCT116 cells NHvnSYpEgXSxdH;4bYNqfHliYYPzZZk> NXPWSGtIPzJiaB?= NXXLSJpjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTB;MD6wNFA4PCEQvF2= MlXsNlE6PTV2NUS=
DU145 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= NIPYd4w1QCCq NVPvbWdXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO NGrsXoIyQDNyM{i0PS=>
RS4:11 cells MlPtVJJwdGmoZYLheIlwdiCjc4PhfS=> Mk\RO|IhcA>? M4LOZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODB6IN88US=> NXz3TYUzOjV5OEW2NFU>
HCT 116 MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;SR49v[2WwdILheIlwdiC5aHnjbEBxem:mdXPld{A2OCViaX7obYJqfGmxbjDv[kBoem:5dHigc4YhcHWvYX6gZ49td25idIXtc5IhUEOWIEGxOkwhUUN3ME2wMlAxODlizszN NWTIUGk6OTF5MUS2NVM>
HeLa cells NFvQNJREgXSxdH;4bYNqfHliYYPzZZk> M{jUSFczKGh? NV3rbJpUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA4OiCqcoOgZpkhemW|YYr1dolvKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlAxODlizszN NVX5UFQ1OjR4Nkm4PFg>
BNL 1ME A.7R.1 cells MYfDfZRwfG:6aXPpeJkh[XO|YYm= NFntWHpEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDVkxiMV3FJGEvP1JwMTDj[YxteyxiSVO1NF0xNjByMEmg{txO MXeyOVc5PTZyNR?=
Calu6 M16zVXBzd2yrZnXyZZRqd25iYYPzZZk> MnHMOFghcA>? NXnEe5NFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZYx2PiCjZoTldkA1QCCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUC9NE4xODB7NDFOwG0> M3LUeVIyPzd2NEm5
melanoma B16 cell MnPyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn6zR49v[2WwdILheIlwdiC5aHnjbEBxem:mdXPld{A2OCViaX7obYJqfGmxbjDv[kBoem:5dHigc4YhdXW{aX7lJI1mdGGwb33hJGIyPiClZXzsJIxqdmVuIFnDOVA:OC5yMEGg{txO M1nPZVEyPzF2NkGz
DU145 cells M1nCUGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1HF[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NX7YdGhYOjB2OU[5NlM>
HCT116 cells M1HzXnBzd2yrZnXyZZRqd25iYYPzZZk> NGLER|I4OiCq MlHxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? M3zxdFIyOTF{MUOw
HCT15 cells MUPQdo9tcW[ncnH0bY9vKGG|c3H5 Mm[1O|IhcA>? NVu0SHZWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MnP1NlEyOTJzM{C=
HL60 cells MlLtVJJwdGmoZYLheIlwdiCjc4PhfS=> NEHOZlA4OiCq MlnCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MljINlE3PjN|MUm=
A10 cells M3PW[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXe4ZmNNPDhiaB?= MWfHdo94fGhiaX7obYJqfGmxbjDv[kBz[XRiQUGwJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MWSyNlA1PDF4NB?=
HUVEC cells NYr4dpR{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVvJWlVxPDhiaB?= MULHdo94fGhiaX7obYJqfGmxbjDv[kBJXV[HQzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> MYGyNlA1PDF4NB?=
HL60 cells NIO0[YJEgXSxdH;4bYNqfHliYYPzZZk> M2TKTFczKGh? NVns[4dMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> MV[yNlE{PjNzMh?=
HL60 cells Mn7vVJJwdGmoZYLheIlwdiCjc4PhfS=> M4L4d|czKGh? MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MX6yNlU4QDFzMR?=
NCI-H522 cells MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXHHOYR2PDhiaB?= NWL3WHRST3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NYTtR2NHOjJ7OEKxNlI>
MDA-MB-435 cells NHLVeplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUO0PEBp M2HPXWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M1jJdVIzQTh{MUKy
OVCAR3 MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vEN|Q5KGh? NVvuTHNLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKzJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO M3LIblIzQTh{MUKy
NCI/ADR-RES cells MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU[0PEBp MULHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MYGyNlk5OjF{Mh?=
PC3 cells MoH2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml7QOFghcA>? M3X6dGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NXK2UoRxOjJ7OEKxNlI>
DU145 cells NILU[XlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3fjclQ5KGh? MV\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NIXSTmYzOjl6MkGyNi=>
MDA-MB-231 cells NHHoXnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV[0PEBp NHHRXWRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NYTZPG1lOjJ7OEKxNlI>
CEM cells M2XOUGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFjMXo44OiCq NXv6SYZTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MYOyNlY4PjJ2Nx?=
HCT116 cells NEfJ[W9EgXSxdH;4bYNqfHliYYPzZZk> M3TvRVczKGh? NWPCb5VZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M3nEU|IzPjd4MkS3
MDA-MB-435 cells NWi4XoJzS3m2b4TvfIlkcXS7IHHzd4F6 M13YeFczKGh? MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NUTpNIplOjJ4N{[yOFc>
HaCaT cells NXv1XG5NWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEijQ3HUJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MYCyN|A3OzRyMR?=
HL60 cells NITJb21Rem:uaX\ldoF1cW:wIHHzd4F6 NHvYUnM4OiCq M1ryb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NIXsfoYzOzFzN{G3NS=>
HL60 cells MW\Qdo9tcW[ncnH0bY9vKGG|c3H5 MYm3NkBp MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KCh|LTi0MFUu\GmvZYTofYx1cGmjen;sMVIugWxrLUKsOU1lcXCqZX75cJRmfHKjen;sbZVuKGK{b33p[IUhfGW|dDygTWM2OD1yLkCwNUDPxE1? NEi1U5QzPTd6NU[wOS=>
HT-29 MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17TO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NYexWIZIOjV4OEmxNVE>
HL60 cells NGPsVopRem:uaX\ldoF1cW:wIHHzd4F6 MXm3NkBp NEG2OGVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MkLLNlA1OjB2M{m=
Hs578T cells MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTucFY1QCCq MknIS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTJM2PziWIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NV3sXodUOjJ7OEKxNlI>
HL60 cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= NXX0TpF2PzJiaB?= MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MXyyN|Q1PTR7Nh?=
SKOV3 cells NV7QcVVsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M33pfFI2Pjh7MUGx
MDA-MB-468 cells MVzDfZRwfG:6aXPpeJkh[XO|YYm= M{\IPVQh\GG7cx?= M{\uU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNDDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNVEh|ryP NYTLcmdFOjR{MUC1NFM>
MCF7 cells NF3GTYpRem:uaX\ldoF1cW:wIHHzd4F6 MkGwO|IhcA>? NWLNVVJCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzMUGg{txO M3rielIzOzJ7NU[x
H460 NFr4OZFEgXSxdH;4bYNqfHliYYPzZZk> NFz4eotEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJidHXzeEwhUUN3ME2wMlAxOTJizszN MnKzNVg4QDN{MEe=
H460 MXHQdo9tcW[ncnH0bY9vKGG|c3H5 MlHhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKNE[wJINmdGy|LDDJR|UxRTBwMECxNlQh|ryP M2rGWFE3PzJ{NkOz
NCI-H460 cells NHfQRVhEgXSxdH;4bYNqfHliYYPzZZk> M3XHZlczKGh? NX\FUpNwS3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVMh|ryP M{jNclE5Ozl4OEW3
OVCAR8 cells MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYq5OkBp M{jIRWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCxdnXy[ZhxemW|c3nu[{BRNWeueXPvdJJwfGWrbjDh[pRmeiB7NjDodpMtKEmFNUC9NE4xODF|IN88US=> M3PjS|IzODR2MU[0
NCI/ADR-RES cells NIfhNmpEgXSxdH;4bYNqfHliYYPzZZk> MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:OC5yMEGzJO69VQ>? NWTheVgyOjN{MUS0OVI>
OVCAR8 cells NVXU[YJ5S3m2b4TvfIlkcXS7IHHzd4F6 NW\CWo4{QTZiaB?= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjhiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhQTZiaILzJIJ6KEerZX3zZUB{fGGrbnnu[{1j[XOnZDDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxRTBwMECxN{DPxE1? NIrQc4gzPTB{NUm5NS=>
NCI/ADR-RES cells MmLtR5l1d3SxeHnjbZR6KGG|c3H5 NHHkNW46PiCq MorPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgPVYhcHK|IHL5JGdq\W2|YTDzeIFqdmmwZz3iZZNm\CCuaXfoeEBucWO{b4Pjc5B6NCCLQ{WwQVAvODBzMzFOwG0> MVmyOVAzPTl7MR?=
OVCAR8 cells MXPDfZRwfG:6aXPpeJkh[XO|YYm= Mk\TR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2wMlAxOTNizszN NHzodmszOzJzNES1Ni=>
HuTu 80 cells MWPQdo9tcW[ncnH0bY9vKGG|c3H5 NXjURo5rPzJiaB?= MmP1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gTJVVfSB6MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzM{eg{txO MWCyNlMzQTV4MR?=
K562 cells NVjmfJJ5S3m2b4TvfIlkcXS7IHHzd4F6 MmDVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{whUUN3ME2wMlAxOTRizszN NWTBfZVMOTl6M{e1PVQ>
NCI/ADR (MDR) cells MoG4SpVv[3Srb36gZZN{[Xl? M3XyNWNmdGxiY4njcIUh[XK{ZYP0JIlvKE6FST;BSHIhME2GUjmgZ4VtdHNiYomgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WsJGlEPTB;MD6wNFE2KM7:TR?= MYOxOlM4PzF6Nx?=
HUVEC MkfxVJJwdGmoZYLheIlwdiCjc4PhfS=> NILJZ|JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVENCCLQ{WwQVAvODBzNTFOwG0> NFq2dZoyPjd{Mk[zNy=>
KB cell MWXQdo9tcW[ncnH0bY9vKGG|c3H5 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIwhdGmwZTDifUBu\XSqeXzlcoUh[my3ZTDkfYUh[XO|YYmsJGlEPTB;MD6wNFE2KM7:TR?= MoG0NVcxOzRzNEe=
KB-VIN10 cell MV;Qdo9tcW[ncnH0bY9vKGG|c3H5 M3TpcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtWmlPOTBiY3XscEBtcW6nIHL5JI1mfGi7bHXu[UBjdHWnIHT5[UBie3OjeTygTWM2OD1yLkCwNVUh|ryP MUSxO|A{PDF2Nx?=
Human SH-SY5Y neuroblastoma cells MX;GeY5kfGmxbjDhd5NigQ>? MonwTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiSIXtZY4hW0hvU2m1XUBv\XW{b3LsZZN1d22jIHPlcIx{NCCLQ{WwQVAvODBzNTFOwG0> NYf6eHF4OTV7NkO3NlI>
SW620 cells MlTKVJJwdGmoZYLheIlwdiCjc4PhfS=> M1PVcVczKGh? NWm0TXZqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW1d4MkCgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMUWyJO69VQ>? NFj5PJgzOjN{OUW2NS=>
Molt4/C8 cells NXHoVnpNWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkjlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{whUUN3ME2wMlAxOTZizszN M1TndFE4ODN2MUWw
ACHN cell MWjQdo9tcW[ncnH0bY9vKGG|c3H5 MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHTyeYchemW|aYP0ZY51KEGFSF6gZ4VtdCCuaX7lJIV5eHKnc4PpcochVUSUMTDifUBCdGGvYYKgRox2\SCjc4PhfUwhUUN3ME2wMlAxOTZizszN M3LmNVE4Ojh4M{mz
Molt4/C8 cells NIH2NppRem:uaX\ldoF1cW:wIHHzd4F6 NYHRNlUyOyCmYYnz M2LKZ2FvfGmycn;sbYZmemG2aY\lJIVn\mWldDDh[4FqdnO2IHj1cYFvKE2xbIS0M2M5KGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NF0xNjByMU[g{txO M1SzNVE4PDF7NkC3

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
+ Expand

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01423149 Completed Choroidal Neovascularization|Myopia Degenerative Mateon Therapeutics March 2005 Phase 2
NCT00077103 Terminated Head and Neck Cancer Case Comprehensive Cancer Center|National Cancer Institute (NCI) November 2003 Phase 1|Phase 2
NCT01570790 Completed Combretastatin A4 Phosphate|Age-related Macular Degeneration|AMD|CNV|Choroidal Neovascularization Johns Hopkins University May 2003 Phase 1|Phase 2
NCT00060242 Completed Head and Neck Cancer Case Comprehensive Cancer Center|National Cancer Institute (NCI) February 2003 Phase 2
NCT00003768 Completed Unspecified Adult Solid Tumor Protocol Specific Case Comprehensive Cancer Center|National Cancer Institute (NCI) September 1998 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID